Abstract:More than 2·7 million individuals worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 187 000 have died from the resulting coronavirus disease 2019 (COVID-19) as of April 25, 2020.1WHOCoronavirus disease 2019 (COVID-19) situation report 96.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-covid-19.pdf?sfvrsn=a33836bb_2Date: April 25, 2020Date accessed: April 26, 2020Google Scholar Despite the common use of immunosuppressive medications, it appears that patients with inflammatory bowel disease (IBD) have a similar risk for COVID-19 to the general population.2SECURE-IBDCOVID-19 in people with inflammatory bowel disease.https://ucalgary.maps.arcgis.com/apps/opsdashboard/index.html#/7f596bdbf4654e19a3a3cf13b6e597deDate accessed: April 26, 2020Google Scholar The management of IBD during and after the pandemic is challenging. The main concerns from a clinician's perspective are the risk for COVID-19 in patients with IBD (especially in those taking immunosuppressive medications or with malnutrition), timely follow-up and monitoring of disease, choice of and change in medical and surgical therapy, feasibility and availability of endoscopic assessment, and protection of health-care providers against SARS-CoV-2 infection.3Mao R Liang J Shen J et al.Implications of COVID-19 for patients with pre-existing digestive diseases.Lancet Gastroenterol Hepatol. 2020; 5: 426-428Summary Full Text Full Text PDF PubMed Scopus (247) Google Scholar, 4Yang H Zhu LR Tian D Inflammatory Bowel Disease GroupChinese Society of GastroenterologyChinese Medical AssociationManagement of patients with inflammatory bowel disease during epidemic of 2019 novel coronavirus pneumonia.Chin J Dig. 2020; 40 (in Chinese).: E001Google Scholar, 5International Organisation for the study of IBDIOIBD update on COVID19 for patients with Crohn's disease and ulcerative colitis.https://www.ioibd.org/ioibd-update-on-covid19-for-patients-withcrohns-disease-and-ulcerative-colitisDate: April 23, 2020Date accessed: April 23, 2020Google Scholar, 6Rubin DT Abreu MT Rai V Siegel CA Management of patients with Crohn's disease and ulcerative colitis during the COVID-19 pandemic: results of an international meeting.Gastroenterology. 2020; (published online April 6.)DOI:10.1053/j.gastro.2020.04.002Summary Full Text Full Text PDF Scopus (170) Google Scholar, 7Rubin DT Feuerstein JD Wang AY Cohen RD AGA clinical practice update on management of inflammatory bowel disease during the covid-19 pandemic: expert commentary.Gastroenterology. 2020; (published online April 10.)DOI:10.1053/j.gastro.2020.04.012Summary Full Text Full Text PDF Scopus (179) Google Scholar Additional concerns have been raised from the patients' perspective, including medical, psychosocial, and financial factors. Therefore, we did a survey involving patients with IBD to analyse their feedback on their care during the early and late phases of the COVID-19 outbreak in China. The anonymous questionnaire was designed by clinicians, registered nurses, and patient representatives and was posted on the China Crohn's and Colitis Foundation's patient portal. 2277 participants completed the survey. 880 (39%) were women and 1397 (61%) men; 1639 (72%) had Crohn's disease and 555 (24%) had ulcerative colitis. 111 (5%) respondents were from Hubei province. Of the 2277 respondents, 1134 (50%) were employed full or part time. Most (934 [82%] of 1134) had to work at home during the pandemic and 443 (39%) reported reduced income (appendix). More than 50% of the respondents reported some degree of mood changes, with the peak of the frequency of moderate-to-severe psychological change in the middle of the outbreak in China—ie, mid-February, 2020. Many (1331 [58%] of 2277) respondents were worried about the risk for SARS-CoV-2 infection for themselves and their family and more than half (1184 [52%]) were concerned about the difficulty in seeing physicians (appendix). Almost three-quarters of patients (1691 [74%]) reported that their disease state was stable during the initial outbreak (from January to March, 2020) and 1842 (81%) reported that their disease remained stable in the later phase (ie, mid-April, 2020). 137 (6%) patients were admitted for IBD flares and 23 (1%) had surgery. 639 (28%) patients used telemedicine—of whom 487 (76%) sought help from IBD health-care providers online—and 847 (37%) of 2277 patients had face-to-face visits. Most patients (1744 [77%]) did not change IBD medications during the outbreak. Of the 533 patients with a change in medications, the main reasons for the change were recommendations from treating physicians (157 [30%]), being unable to receive intravenous infusions (151 [28%]), and the availability of physicians or facilities (148 [28%]). Most respondents (1606 [71%] of 2277) were still able to obtain oral medications online (1125 [49%]) or from hospital pharmacies as before (481 [21%]). By mid-April, 2020, most (1628 [71%]) were able to obtain oral medicines from their hospital pharmacies as before (appendix). The COVID-19 pandemic has posed challenges to every aspect of respondents' lives. Measures to curtail the virus, such as shelter-in-place, government mandates for postponing elective procedures, restriction of transportation, and the reassignment of gastroenterologists or IBD health-care providers, can interfere with routine or emergent care. Most patients with IBD experienced stable disease during the early and current phases of the outbreak and those individuals did not have to change their medications. Our survey data suggest that the impact of the COVID-19 outbreak on medical management of IBD was largely related to logistics. Restructuring IBD care, such as personnel reassignment, infusion service availability, drug delivery, and telemedicine, have been proposed as being important for IBD management during such a pandemic.8Allocca M Fiorino G Furfaro F et al.Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic.Clin Gastroenterol Hepatol. 2020; (published online April 15.)DOI:10.1016/j.cgh.2020.04.028Summary Full Text Full Text PDF PubMed Scopus (40) Google Scholar Our survey shows that a quarter of patients sought care via telemedicine with their IBD physicians. There was also increased use of online delivery of oral medications. Mental health issues have been reported by both patients and health-care providers during the outbreak.9Percudani M Corradin M Moreno M Indelicato A Vita A Mental health services in Lombardy during COVID-19 outbreak.Psychiatry Res. 2020; 288112980Crossref PubMed Scopus (105) Google Scholar, 10Zhang WR Wang K Yin L et al.Mental health and psychosocial problems of medical health workers during the COVID-19 epidemic in China.Psychother Psychosom. 2020; (published online April 9.)DOI:10.1159/000507639Crossref Scopus (985) Google Scholar Mental health issues are particularly important in patients with diseases of long duration, such as IBD. Our survey suggests that although patients' moods were affected by concerns about psychosocial and economic issues, their disease course was not affected. Respondents were concerned about the risk of infection and worried about access to health care. More than 50% of respondents had mood changes and their mood changes appeared to improve as the pandemic trend was flattening. More than 80% of employed respondents had to work from home and 40% of the respondents reported a reduced income. The financial impact can be long lasting, which could affect the affordability of and adherence to medical care. This could eventually alter disease outcomes. The results from this large survey suggest that the COVID-19 pandemic affects patients with IBD medically, psychosocially, and financially. Most respondents' disease remained stable. Respondents using maintenance therapy and those requiring medication adjustments because of disease flares often met logistical challenges. The availability of telemedicine and online drug delivery services might have eased some of the burden. Psychosocial and economic effects of the pandemic on IBD care are common. The long-lasting effects will need to be studied over time. FAF has served as a consultant for Bristol-Myers Squibb, Braintree Labs, Gilead, GlaxoSmithKline, Innovation Pharmaceuticals, Janssen, Pfizer, and Sebela, and sits on a data safety monitoring board for Lilly and Theravance. CNB has served on advisory boards for AbbVie Canada, Roche Canada, Janssen Canada, Takeda Canada, and Pfizer Canada; has been a consultant for Mylan Pharmaceuticals; and has received educational grants from AbbVie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada; and acted as a speaker for Janssen Canada, AbbVie Canada, Medtronic Canada, and Takeda Canada. BS has served as a consultant and speaker for AbbVie, Janssen, and Takeda. YC, SH, HW, J-JZ, and RPK declare no competing interests. The authors are grateful to support from surveyed patients. The study was approved by the ethics committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China). YC, SH, and HW contributed equally to this Comment. Download .pdf (.43 MB) Help with pdf files Supplementary appendix

Abstract:The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China, in December, 2019, now affects the whole world. As of March 8, 2020, more than 105 000 laboratory-confirmed cases and more than 3500 deaths in over 100 countries had been reported. Since SARS-CoV-2 RNA was first detected in a stool specimen of the first reported COVID-19 case in the USA,1Holshue ML DeBolt C Lindquist S et al.First case of 2019 novel coronavirus in the United States.N Engl J Med. 2020; (published online March 5.)DOI:10.1056/NEJMoa2001191Crossref PubMed Scopus (4278) Google Scholar much attention has been paid to the study and reporting of gastrointestinal tract infection of SARS-CoV-2. According to a study2Guan W Ni Z Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032Crossref Google Scholar including 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in China as of Jan 29, 2020, nausea or vomiting, or both, and diarrhoea were reported in 55 (5·6%) and 42 (3·8%) patients. Autopsy studies are crucial to help understand the involvement of COVID-19 in the digestive system; however, to date, there has been only one autopsy report3Liu Q Wang R Qu G et al.Macroscopic autopsy findings in a patient with COVID-19.J Forensic Med. 2020; 36 (in Chinese).: 1-3Google Scholar for a man aged 85 years with COVID-19, which showed segmental dilatation and stenosis in the small intestine. Whether this finding is secondary to COVID-19 or a pre-existing gastrointestinal comorbidity is unknown. COVID-19 has implications for the management of patients with pre-existing digestive diseases. Indeed, the presence and number of comorbidities is associated with poorer clinical outcome in patients with COVID-19. In the study2Guan W Ni Z Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032Crossref Google Scholar of 1099 patients with laboratory-confirmed COVID-19, 261 (23·7%) patients with COVID-19 reported having at least one comorbidity, with hypertension, diabetes, and coronary heart disease being the most common. In this study,2Guan W Ni Z Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032Crossref Google Scholar 23 (2·1%) patients had hepatitis B infection; chronic hepatitis B infection did not seem to be associated with a severe course of COVID-19.2Guan W Ni Z Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032Crossref Google Scholar Abnormal liver function tests, including elevated aspartate aminotransferase, alanine aminotransferase, and total bilirubin were noted.2Guan W Ni Z Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032Crossref Google Scholar Liver abnormalities in patients with COVID-19 might be due to viral infection in liver cells but could also be due to other causes such as drug toxicity and systemic inflammation.4Zhang C Shi L Wang FS Liver injury in COVID-19: management and challenges.Lancet Gastroenterol Hepatol. 2020; (published online March 4)https://doi.org/10.1016/S2468-1253(20)30057-1Summary Full Text Full Text PDF Scopus (1321) Google Scholar Data suggest that liver injury is more prevalent in severe cases than in mild cases of COVID-19.4Zhang C Shi L Wang FS Liver injury in COVID-19: management and challenges.Lancet Gastroenterol Hepatol. 2020; (published online March 4)https://doi.org/10.1016/S2468-1253(20)30057-1Summary Full Text Full Text PDF Scopus (1321) Google Scholar However, data about other underlying chronic liver conditions such as non-alcoholic fatty liver disease, alcohol-related liver disease, and autoimmune hepatitis, and their effect on prognosis of COVID-19 needs to be further evaluated. Liver transplantation might involve a risk of transmission of viral infection from donor to recipient, as shown in the previous SARS outbreak, and therefore donor screening and testing is crucial.5Kumar D Tellier R Draker R Levy G Humar A Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening.Am J Transplant. 2003; 3: 977-981Crossref PubMed Scopus (122) Google Scholar Although many patients had comorbidities in the reported series,2Guan W Ni Z Hu Y et al.Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; (published online Feb 28.)DOI:10.1056/NEJMoa2002032Crossref Google Scholar none had been a transplant recipient. Transplant clinicians are encouraged to follow guidance issued by The Transplantation Society,6The Transplantation SocietyGuidance on coronavirus disease 2019 (COVID-19) for transplant clinicians.https://tts.org/23-tid/tid-news/657-tid-update-and-guidance-on-2019-novel-coronavirus-2019-ncov-for-transplant-id-cliniciansGoogle Scholar as well as local health department guidelines for isolating, quarantining, testing, and monitoring returned travellers from endemic areas. Patients with cancer in general are more susceptible to infection due to their immunocompromised status caused by the malignancy and anticancer treatments. However, whether patients with gastrointestinal cancers are more likely to be infected with SARS-CoV-2 than healthy individuals remains unknown. In a recent nationwide analysis from China,7Liang W Guan W Chen R et al.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.Lancet Oncol. 2020; (published online Feb 14.)DOI:10.1016/S1470-2045(20)30096-6Summary Full Text Full Text PDF PubMed Scopus (3273) Google Scholar 18 (1%) of 1590 COVID-19 cases had a history of cancer. Among these 18 cases, three had a history of colorectal cancer (one colonic tubular adenocarcinoma, one rectal carcinoma, and one colorectal carcinoma).7Liang W Guan W Chen R et al.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.Lancet Oncol. 2020; (published online Feb 14.)DOI:10.1016/S1470-2045(20)30096-6Summary Full Text Full Text PDF PubMed Scopus (3273) Google Scholar Patients with COVID-19 and cancer were observed to have a higher risk of severe events; several strategies have been proposed, such as intentional postponing of adjuvant chemotherapy or elective surgery on a patient-by-patient basis, stronger personal protection provisions, and more intensive surveillance or treatment.7Liang W Guan W Chen R et al.Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.Lancet Oncol. 2020; (published online Feb 14.)DOI:10.1016/S1470-2045(20)30096-6Summary Full Text Full Text PDF PubMed Scopus (3273) Google Scholar Given the use of biologics and immunosuppressive agents, whether patients with inflammatory bowel disease (IBD) are more susceptible to SARS-CoV-2 infection has raised great concern. Currently no patients with IBD have been reported to be infected with SARS-CoV-2 in the IBD Elite Union, which incorporates the seven largest IBD referral centres in China with more than 20 000 patients with IBD.8Mao R Chen MH Networked Clinical study collaboration on inflammatory bowel disease in China.Am J Gastroenterol. 2018; 113: 1266Crossref PubMed Scopus (8) Google Scholar Furthermore, no patients with IBD with SARS-CoV-2 infection have been reported from the three largest tertiary IBD centres in Wuhan (Tongji Hospital, Union Hospital, and Zhongnan Hospital) at the time that this manuscript was prepared (March 8, 2020). Several strategies have been implemented in China to minimise the potential risk of SARS-CoV-2 infection in patients with IBD since the outbreak of COVID-19. First, the Chinese IBD Society issued official guidelines for managing patients with IBD in early February 2020.9Chinse Society of IBD Managing IBD patients during the outbreak of COVID-19.Chin J Dig. 2020; 40: E001Google Scholar The guidelines include practical recommendations on the use of immunosuppressive agents and biologics, diet, and intentional postponement of elective surgery and endoscopy, as well as personal protection provisions; these are outlined in the panel. Second, the China Crohn's & Colitis Foundation has organised a group of volunteer gastroenterologists that specialise in IBD to offer online consultancy to patients with IBD since Jan 29, 2020. Third, an online virtual IBD visit programme has been initiated in some IBD centres, which provides convenient and cost-effective care, and could potentially reduce the risk of SARS-CoV-2 infection by avoiding close contact with infected patients in public areas. With the increasing concern from patients with IBD globally, helpful online resources about COVID-19 have been provided by international non-profit organisations such as Crohn's Colitis of Foundation America and Crohn's & Colitis UK.10Crohn's Colitis FoundationWhat IBD patients should know about the 2019 novel coronavirus (COVID-19).https://www.crohnscolitisfoundation.org/what-ibd-patients-should-know-about-2019-novel-coronavirus-covid-19Google Scholar, 11Crohn's & Colitis UK Novel coronavirus (COVID-19) advice.https://www.crohnsandcolitis.org.uk/news/updated-wuhan-novel-coronavirus-adviceGoogle Scholar Such guidance and advice should be delivered urgently to health-care workers as well as patients with IBD.PanelKey recommendations for managing patients with IBD during the COVID-19 epidemicPotential risk factors for SARS-CoV-2 infection•Patients with inflammatory bowel disease (IBD) on immunosuppressive agents•Patients with active-stage IBD with malnutrition•Elderly patients with IBD•Patients with IBD frequently visiting medical clinic•Patients with IBD with underlying health conditions, such as hypertension and diabetes•Patients with IBD who are pregnantMedication for patients with IBD•Continue current treatment if disease is stable, and contact your doctor for suitable medicine if disease has flared•Use of mesalamine should be continued and should not increase the risk of infection•Corticosteroid use can be continued, but be cautious of possible side-effects•A new prescription of immunosuppressant or increase in dose of an ongoing immunosuppressant is not recommended in epidemic areas.•Use of biologics such as the anti-TNFs infliximab or adalimumab should be continued•If infliximab infusion is not accessible, switching to adalimumab injection at home is encouraged•Vedolizumab use can be continued due to the specificity of the drug for the intestine•Ustekinumab use can be continued, but starting ustekinumab requires infusion centre visits and therefore is not encouraged•Enteral nutrition might be used if biologics are not accessible•Tofacitinib should not be newly prescribed in epidemic areas unless there are no other alternativesSurgery and endoscopy•Postpone elective surgery and endoscopy•Screening for COVID-19 (complete blood count, IgM or IgG, nucleic acid detection, and chest CT) before emergency surgeryPatients with IBD and fever *Fever is the most common reported symptom in COVID-19. •Contact your IBD doctor about potential option to visit fever outpatient clinic with personal protection provisions if temperature continues over 38°C•Suspend the use of immunosuppressant and biological agents after consultation with your IBD doctor, and follow appropriate local guidance for suspected COVID-19 if COVID-19 cannot be ruled outCOVID-19=coronavirus disease 2019. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. Potential risk factors for SARS-CoV-2 infection •Patients with inflammatory bowel disease (IBD) on immunosuppressive agents•Patients with active-stage IBD with malnutrition•Elderly patients with IBD•Patients with IBD frequently visiting medical clinic•Patients with IBD with underlying health conditions, such as hypertension and diabetes•Patients with IBD who are pregnant Medication for patients with IBD •Continue current treatment if disease is stable, and contact your doctor for suitable medicine if disease has flared•Use of mesalamine should be continued and should not increase the risk of infection•Corticosteroid use can be continued, but be cautious of possible side-effects•A new prescription of immunosuppressant or increase in dose of an ongoing immunosuppressant is not recommended in epidemic areas.•Use of biologics such as the anti-TNFs infliximab or adalimumab should be continued•If infliximab infusion is not accessible, switching to adalimumab injection at home is encouraged•Vedolizumab use can be continued due to the specificity of the drug for the intestine•Ustekinumab use can be continued, but starting ustekinumab requires infusion centre visits and therefore is not encouraged•Enteral nutrition might be used if biologics are not accessible•Tofacitinib should not be newly prescribed in epidemic areas unless there are no other alternatives Surgery and endoscopy •Postpone elective surgery and endoscopy•Screening for COVID-19 (complete blood count, IgM or IgG, nucleic acid detection, and chest CT) before emergency surgery Patients with IBD and fever *Fever is the most common reported symptom in COVID-19. •Contact your IBD doctor about potential option to visit fever outpatient clinic with personal protection provisions if temperature continues over 38°C•Suspend the use of immunosuppressant and biological agents after consultation with your IBD doctor, and follow appropriate local guidance for suspected COVID-19 if COVID-19 cannot be ruled out COVID-19=coronavirus disease 2019. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. The comorbidity spectrum of digestive conditions and its impact on treatment and outcome of COVID-19 remains largely unknown. Further data need to be analysed from the COVID-19 cohort established by the National Health Commission of the People's Republic of China, which would help to more precisely ascertain the risk of SARS-CoV-2 infection in patients with digestive comorbidities such as IBD. These data and experience with guidance on how to manage patients with underlining comorbidities in China could facilitate integrated care for patients globally. For WHO Coronavirus Disease 2019 (COVID-19) Situation Report 48 see https://www.who.int/docs/default-source/coronaviruse/situationreports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4 For WHO Coronavirus Disease 2019 (COVID-19) Situation Report 48 see https://www.who.int/docs/default-source/coronaviruse/situationreports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4 This online publication has been corrected. The corrected version first appeared at thelancet.com/gastrohep on May 8, 2020 This online publication has been corrected. The corrected version first appeared at thelancet.com/gastrohep on May 8, 2020 We declare no competing interests. We thank the members of Chinese IBD Elite Union, Chinese Society of IBD and Chinese IBD Quality Care Evaluation Center Committee (IBDQCC) for their collaboration. RM and JL contributed equally. Download .pdf (.53 MB) Help with pdf files Chinese translation of the full text Correction to Lancet Gastroenterol Hepatol 2020; 5: 425–27Mao R, Liang J, Shen J, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol 2020; 5: 425–27—The fourth sentence of the third paragraph of this Comment should read "In this study,2 23 (2·1%) patients had hepatitis B infection; chronic hepatitis B infection did not seem to be associated with a severe course of COVID-19.2" This correction has been made to the online version as of May 8, 2020. Full-Text PDF Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, ChinaAs recently outlined by Ren Mao and colleagues1 in The Lancet Gastroenterology & Hepatology, patients with inflammatory bowel disease (IBD) are at increased risk of opportunistic infections. Particular attention is therefore required for these patients during the ongoing coronavirus disease 2019 (COVID-19) pandemic. Full-Text PDF

Prevention of COVID-19 in Patients with Inflammatory Bowel Disease in Wuhan, China

Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan, China

Patterns of Endoscopy During COVID-19 Pandemic: a Global Survey of Interventional Inflammatory Bowel Disease Practice

Prevention of COVID-19 in Patients with IBD – Authors' Reply

Patterns of Care for Inflammatory Bowel Disease in China During the COVID-19 Pandemic.

Practice Patterns of Medical Management of Inflammatory Bowel Disease During Pandemic of COVID-19: A Global Survey of Health Care Providers

Insufficient awareness and vaccination practices for inflammatory bowel disease patients in China: A multi-center survey of Chinese gastroenterologists

Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?

COVID-19 and inflammatory bowel disease: A pathophysiological assessment

The Symptoms and Medications of Patients with Inflammatory Bowel Disease in Hubei Province after COVID-19 Epidemic

Risks of Cardiovascular Events in Patients with Inflammatory Bowel Disease in China: A Retrospective Multicenter Cohort Study

Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China

Implications of COVID-19 for Patients with Pre-Existing Digestive Diseases

Opportunistic infections changed before and after SARS-CoV-2 infection in inflammatory bowel disease patients: a retrospective single-center study in China

Retrospective Survey of 452 Patients with Inflammatory Bowel Disease in Wuhan City, Central China

COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal

Gastrointestinal Insights During the COVID-19 Epidemic.

Epidemiological, Clinical and Virological Characteristics of 74 Cases of Coronavirus-Infected Disease 2019 (COVID-19) with Gastrointestinal Symptoms

Digestive system involvement of novel coronavirus infection: Prevention and control infection from a gastroenterology perspective

Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas

P899 Inflammatory Bowel Disease Patients Show More Recognizable Digestive Symptoms of COVID-19: A Questionnaire Study